日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting

RIBBIT研究的最终结果:一项随机III期研究,旨在评估一线治疗中接受瑞博西尼联合内分泌治疗或化疗(伴或不伴贝伐珠单抗)的转移性激素受体阳性、HER2阴性乳腺癌患者的疗效和生活质量。

Decker, Thomas; Zaiss, Matthias; Klein, Dunja; Hahn, Antje; Hagen, Volker; La Rosée, Paul; Liersch, Rüdiger; Wolff, Thomas; Niemeier, Beate; Hillebrand, Larissa E; Lennartz, Carolin; Chiabudini, Marco; Bengsch, Fee; Indorf, Martin; Marschner, Norbert

The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

INFINITY 研究方案:一项回顾性队列研究,旨在探讨生物标志物驱动的精准肿瘤学在常规临床实践中的决策制定和临床影响。

Martens, Uwe M; Schröder, Jan; Bengsch, Fee; Sellmann, Ludger; Busies, Sabine; Frank-Gleich, Stefanie; Zaiss, Matthias; Decker, Thomas; Schneeweiss, Andreas; Schuler, Martin; Grebhardt, Sina; Zacharias, Stefan; Marschner, Norbert; Kasenda, Benjamin; Potthoff, Karin; Vannier, Corinne

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery

胰腺癌基因工程小鼠模型:KPC模型(LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre)、其变体及其在免疫肿瘤药物发现中的应用

Lee, Jae W; Komar, Chad A; Bengsch, Fee; Graham, Kathleen; Beatty, Gregory L

Comprehensive analysis of the ubiquitinome during oncogene-induced senescence in human fibroblasts.

对人类成纤维细胞癌基因诱导衰老过程中泛素组的全面分析

Bengsch Fee, Tu Zhigang, Tang Hsin-Yao, Zhu Hengrui, Speicher David W, Zhang Rugang